DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Bid/Ask 01:51:31 28/05/2024 pm IST | After market 11:47:31 pm | |||
| 0.69 EUR | +1.47% |
|
0.725 | +5.07% |
| 1 month | +36.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.69 | +1.47% |
| 27/24/27 | 0.68 | -6.85% |
| 24/24/24 | 0.73 | -1.35% |
| 23/24/23 | 0.74 | -2.63% |
| 22/24/22 | 0.76 | +11.76% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 01:51 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7M |
| ISIN | DE000MG0D7M3 |
| Date issued | 18/03/2024 |
| Strike | 400 $ |
| Maturity | 21/03/2025 (297 Days) |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.09 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | 0.06 € |
| Spread % | 8.00% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
229.6
USD
Average target price
363.9
USD
Spread / Average Target
+58.49%
- Stock Market
- Certificates
- Certificat
